Summary
DexCom, Inc., in its 2011 10-K filing, reported significant revenue growth driven by its SEVEN PLUS continuous glucose monitoring system. The company is focused on expanding its product offerings and market reach, including development of in-hospital solutions and partnerships for insulin pump integration. Despite strong revenue increases, DexCom continued to incur net losses, underscoring the high R&D and SG&A expenses associated with its growth strategy and the medical device market. Key investor considerations include the company's progress in gaining market acceptance for continuous glucose monitoring, the importance of reimbursement from third-party payors, and the ongoing legal dispute with Abbott Diabetes Care. DexCom's future success hinges on its ability to navigate regulatory pathways, secure broader reimbursement, manage manufacturing scale-up, and continue product innovation in a competitive landscape.
Financial Highlights
49 data points| Revenue | $76.30M |
| Cost of Revenue | $40.40M |
| Gross Profit | $35.90M |
| R&D Expenses | $29.60M |
| SG&A Expenses | $51.10M |
| Operating Expenses | $80.70M |
| Operating Income | -$44.80M |
| Interest Expense | $0 |
| Net Income | -$44.70M |
| EPS (Basic) | $-0.17 |
| Shares Outstanding (Basic) | 262.40M |
Key Highlights
- 1Product revenue increased significantly, reaching $65.9 million in 2011 compared to $40.2 million in 2010, primarily due to increased sales volume of the SEVEN PLUS system.
- 2The company reported a net loss of $44.7 million for 2011, reflecting substantial investments in research and development and selling, general, and administrative expenses.
- 3DexCom is actively pursuing product development and partnerships, including integrating its technology into insulin pumps from Animas, Insulet, Roche, and Tandem, and developing an in-hospital glucose monitoring system (GlucoClear).
- 4Reimbursement remains a critical factor for widespread adoption, with the company actively working with seven major private third-party payors for coverage policies, though Medicare coverage is still pending.
- 5A significant risk factor highlighted is the ongoing patent infringement litigation with Abbott Diabetes Care, which could materially impact the company's ability to sell its key products.
- 6The company is also focused on expanding its sales and marketing infrastructure, including a direct sales force and distribution partnerships, to drive market penetration.
- 7DexCom experienced an FDA warning letter in February 2010 regarding sensor wire fractures and labeling, but reported to have taken corrective actions and received notification of adequate remediation by November 2010.